Quarterly ResultMay 13, 2026, 04:03 PM
Aquestive Q1 Revenue $14.4M; Net Loss $8.1M; Secures $150M Debt Facility
AI Summary
Aquestive Therapeutics reported improved Q1 2026 financial results, with total revenues increasing to $14.4 million and net loss significantly decreasing to $8.1 million. The company also secured a new $150 million debt facility with Oaktree Capital Management, which is expected to save $45 million in principal payments over three years and extend its cash runway. Additionally, Aquestive reaffirmed its guidance to resubmit the Anaphylm™ NDA in Q3 2026 and completed a Phase 1 study for AQST-108 with no safety issues.
Key Highlights
- Secured new $150 million debt facility with Oaktree Capital Management.
- Refinancing existing debt will save $45 million in principal payments over three years.
- Reaffirms Anaphylm NDA resubmission target for Q3 2026.
- Total revenues rose 66% to $14.4 million in Q1 2026 from $8.7 million YoY.
- Net loss decreased to $8.1 million in Q1 2026 from $22.9 million YoY.
- Non-GAAP adjusted EBITDA loss improved to $1.7 million from $17.6 million YoY.
- Completed AQST-108 Phase 1 study with no safety issues observed.
- Cash and cash equivalents were $110.7 million as of March 31, 2026.